Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full year 2024, along with significant updates across its clinical programs. The company, …
Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled to take place on Monday, March 3, 2025, …
Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development program at major scientific conferences, presenting data on the first 10 patients treated …
Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its investigational CD19-CAR T cell therapy, resecabtagene autoleucel (rese-cel), during two prominent scientific conferences this …
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its participation in Guggenheim’s SMID Cap Biotech Conference, scheduled for Wednesday, February 5, 2025, at 10:30 a.m. ET in New …
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has revealed significant progress in its pipeline and operations, underscoring its focus on advancing rese-cel, a cell therapy candidate for autoimmune diseases. …
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) recently presented encouraging clinical data for its investigational therapy, CABA-201, at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. …
Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has released its financial results for the third quarter of 2024, alongside updates on its clinical trial programs. A key highlight includes …
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced its financial results for the second quarter ended June 30, 2024, along with key business updates.
Cabaletta Bio Reports Q2 2024 Financial Results and Provides Business Update Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has released positive preliminary clinical data from its Phase 1/2 trials of CABA-201, a new potential treatment option for patients with autoimmune …
Cabaletta Bio Reports Promising Early Results for New Autoimmune Disease Treatment Read More